United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $506.59, for a total value of $4,812,605.00. Following the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $164,359,579.37. The trade was a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Stock Performance

United Therapeutics stock traded up $9.79 during midday trading on Tuesday, reaching $518.27. The stock had a trading volume of 366,401 shares, compared to its average volume of 491,932. United Therapeutics Corporation has a twelve month low of $302.19 and a twelve month high of $609.35. The stock has a market capitalization of $22.23 billion, a PE ratio of 18.54, a price-to-earnings-growth ratio of 1.69 and a beta of 0.59. The stock’s 50-day simple moving average is $535.22 and its 200 day simple moving average is $536.38.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm’s revenue was down 1.9% on a year-over-year basis. During the same period in the prior year, the firm posted $6.41 earnings per share. Equities analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Torren Management LLC bought a new position in shares of United Therapeutics during the fourth quarter worth about $26,000. Activest Wealth Management raised its stake in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares in the last quarter. Fiduciary Financial Advisors acquired a new stake in United Therapeutics during the second quarter valued at approximately $30,000. WealthCollab LLC lifted its holdings in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the last quarter. Finally, Rakuten Securities Inc. grew its position in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on UTHR. Weiss Ratings upgraded shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday. Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a research report on Thursday, August 6th. Bank of America cut their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. JPMorgan Chase & Co. upped their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Finally, TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.